This is an Open Access article licensed under the terms of the Creative Commons AttributionNonCommercial 3.0 Unported license (CC BY-NC) (www.karger.com/OA-license), applicable to the online version of the article only. Distribution permitted for non-commercial purposes only. Resveratrol has been shown to exert anti-inflammatory and antioxidant effects, while sodium alginate is a common pharmaceutic adjuvant with antioxidative and immunomodulatory properties. We performed an animal study to investigate the effect of sodium alginate addition to resveratrol on acute gouty arthritis. Methods: Twenty-four SPF Wistar mice were randomized to four groups receiving the combination of sodium alginate and resveratrol, resveratrol alone, colchicine, and placebo, respectively. Acute gouty arthritis was induced by injection of 0.05 ml monosodium urate (MSU) solution (25g/mL) into ankle joint cavity. IL-1β, CCR5, and CXCL10 levels in both serum and synovial fluid were measured using ELISA. NLRP3 expression in the synovial tissues was measured using western plot. Results: The combination of sodium alginate and resveratrol significantly reduced synovial levels of IL-1β, CCR5, and CXCL10 when compared with colchicines, and all P values were less than 0.0001. The combination of sodium alginate and resveratrol was also superior to resveratrol in terms of both serum levels and synovial levels of IL-1β, CCR5, and CXCL10. In addition, resveratrol, with or without sodium alginate, could reduce NLRP3 expression obviously in the synovial tissues. Conclusion: The combination of sodium alginate and resveratrol has better effect over colchicines in treating MSU-induced acute gouty arthritis.
Introduction
Gout is a common arthritis caused by deposition of monosodium urate (MSU) crystals within joints after chronic hyperuricaemia [1] . Acute gouty arthritis is an inflammatory disease resulting from the precipitation of MSU crystals in joints and periarticular tissues, and it's a major cause of decreased quality of life in patients with gout [2, 3] . In acute gouty arthritis, MSU crystals stimulate the production of NLRP3 and interleukin-1β (IL-1β) [4] . IL-1β secretion can induce further production of IL-1β and other inflammatory mediators such as tumor necrosis factor α (TNF-α), interleukin-6 (IL-6), and interleukin-8 (IL-8), which further lead to altered expression of adhesion molecules and chemokines, neutrophil recruitment, and a series of intense inflammation [4] . C-X-C motif chemokine 10 (CXCL10) is a 10 kDa protein and a Th1-chemokine, which regulates immune responses through the activation and recruitment of leukocytes [5] . Recent studies have shown that CXCL10 expression is increased in various autoimmune diseases such as rheumatoid arthritis (RA) [5] . CC chemokine receptor 5 (CCR5) is a seven-transmembrane G protein-coupled receptor (GPCR) which regulates memory/effector T-lymphocytes, macrophages, and immature dendritic cells [6, 7] . Since inflammation is a critical factor in the etiology of acute gouty arthritis and CCR5/CXCL10 have important roles in the immune responses and immunity, researches on CCR5/CXCL10 may provide new therapeutic targets for acute gouty arthritis. Resveratrol has received tremendous attention over the past couple of decades because of its benefits in several human disease models, including antioxidant effect, anti-inflammatory effect, immune regulation, and cancer chemoprevention [8] [9] [10] . Recent studies have shown that resveratrol also has good anti-inflammatory effects in rats with osteoarthritis [8, 11] . Sodium alginate is a common pharmaceutic adjuvant with antioxidative and immunomodulatory property [12] [13] [14] . We performed an animal study to investigate the effect of sodium alginate addition to resveratrol on acute gouty arthritis.
Materials and Methods
Mice SPF Wistar male mice were from Qingdao Drug Control Institute, Qingdao, China (License number: SCXKLU20080002). All animals used for the experiments were ages 6-10 weeks with weight 180 ± 30 g. Twenty-four SPF Wistar mice were randomized to four groups (6 in each group) receiving the combination of Sodium alginate and resveratrol, resveratrol alone, colchicines, and placebo, respectively. Mice in the colchicine group was given colchicines (1mg·kg
), mice in the resveratrol alone group were given resveratrol (500 mg·kg
), mice in the combination group was given resveratrol (500 mg·kg
) and sodium alginate 500 mg·kg
, while the placebo group was given normal saline. The experiments were approved by the Qingdao University Animal Ethics Committee and carried out in accordance with the Committee's guidelines for the care of animals.
Preparation of MSU solution 1 g uric acid was boiled in 200 ml of NaOH (6ml, 1N)/double-distilled water (194 ml) until completely dissolved. The PH of uric acid solution was adjusted to 7.2 with HCL (1N). The uric acid solution was then filtered sterile (0.2-μm filter) and stored at 4°C for 24 hours to allow crystal formation. The resulting MSU crystals were then washed and air-dried under sterile conditions. 250mg MSU crystals were added to 10 ml of saline (9ml)/ Polysorbate -80 (1 ml), and the solution was further heated and stirred, leading to 10ml solution of MSU (25mg/ml).
Model of MSU-induced acute gouty arthritis
After 4-day gavage, all mice were weighed again. 1h after the last gavage and prior to MSU injection, the right ankle circumference was measured with tie-line method. In all four groups, acute gouty arthritis was induced by injection of 0.05ml MSU solution (25g/mL) into the right ankle joint cavity.
NLRP3 expression in synovial tissues
NLRP3 expression was measured by BCA method through the homogenate of synovial tissues of right ankle joints in ice bath. After electrophoresis of 12% SDS-PAGE, NLRP3 was transferred to PVDF membrane, and then was blocked by 5% nonfat milk powder for 2 hours. Primary antibody incubation was then overnight performed with the corresponding antibodies of NLRP3 and β-actin at 4 ℃. After washing by PBST and PBS, the secondary antibody incubation was further performed using corresponding secondary antibodies. The NLRP3 protein was developed using electrochemiluminescence reagent, and the density of each band was measured by densitometry using Quantity One software according to the manufacturer's instructions. Levels of target proteins were normalized to β-actin values.
Statistical analysis
The statistical analyses were performed using SPSS 17.0. Comparisons between the treatment groups were analyzed by two-tailed Student's t test. Results are expressed as the mean ± standard error of the mean (SEM). P value > 0.05 was considered as statistically significant.
Results

MSU-induced joint swelling
There was no obvious difference in the joint swelling index of mice among all those four groups at baseline (P > 0.05). The combination of sodium alginate and resveratrol significantly suppressed the MSU-induced joint swelling when compared with resveratrol alone at 6h after MSU injection (P = 0.007). However, there was no obvious difference in the MSU-induced joint swelling at 6h between the combination and the colchicine group (P > 0.05). At 24h after MSU injection, all three treatment groups had significantly lower MSUinduced joint swelling than that in the placebo group (P < 0.05), while there was no obvious difference in those three treatment groups (P > 0.05) (Fig. 1) . 
Levels of IL-1β, CCR5, and CXCL10 in serum and synovial fluid
The combination of sodium alginate and resveratrol significantly reduced serum levels of IL-1β, CCR5, and CXCL10 when compared with colchicines, and the P values were 0.0001, 0.002 and 0.03, respectively (Fig. 2) . In addition, the combination of sodium alginate and resveratrol was also superior to resveratrol in terms of serum levels of IL-1β, CCR5, and CXCL10 (Fig. 2) .
The combination of sodium alginate and resveratrol significantly reduced synovial levels of IL-1β, CCR5, and CXCL10 when compared with colchicines, and all three P values were less than 0.0001 (Fig. 3) . In addition, the combination of sodium alginate and resveratrol was also superior to resveratrol alone in decreasing synovial levels of IL-1β, CCR5, and CXCL10 (Fig. 3) . 
NLRP3 expression in synovial tissues
As shown in the Fig. 4 , compared with the colchicines group, resveratrol, with or without sodium alginate, could reduce NLRP3 expression obviously in the synovial tissues of mice with acute gouty arthritis (P < 0.05, Fig. 4 ).
Discussion
Gout is a common arthritis caused by deposition of monosodium urate (MSU) crystals within joints after chronic hyperuricaemia [1] . Obesity and hypertriglyceridemia have been identified as risk factors of gout [15, 16] . As the rapid increasing incidence of obesity and hypertriglyceridemia in the population [17] [18] [19] , the gout's prevalence will increase obviously. Currently, there is still lack of effective treatment for acute gouty arthritis, and more researches are needed to further develop promising drugs.
In acute gouty arthritis, MSU crystals activate the NLRP3 inflammasome which further leads to IL-1β secretion [4, 20, 21 ]. It's has been well known that NLRP3 and IL-1β is key mediators of the inflammatory response and it plays a central role in the MSU-induced inflammation in the development of acute gouty arthritis. In present study, we found that resveratrol, with or without sodium alginate, could reduce NLRP3 expression obviously in the synovial tissues of mice with acute gouty arthritis (Fig. 4) . The finding above indicates that resveratrol may treat acute gouty arthritis through inhibiting NLRP3 expression.
IL-1β can induce the expression of endothelial cells, increase the activity of macrophages and granulocytes, and stimulate monocyte-macrophages to express IL-6, IL-8 and TNF-α and other secondary inflammatory cytokines [4] . Therefore, inhibition of IL-lβ is a promising treatment of acute gouty arthritis, and some effective biologic agents targeting IL-1β have been developed against acute gouty arthritis such as IL-1β antagonist Canakinumab. In present study, the combination of sodium alginate and resveratrol significantly reduced serum levels of IL-1β when compared with colchicines or resveratrol alone. The superior effect in the combination group suggests that sodium alginate in combination with resveratrol is a promising therapeutic method for acute gouty arthritis by the anti-inflammatory effect.
Chemokines coordinate leukocyte migration in immunity and inflammation and have been implicated in the pathogenesis of many human diseases [22, 23] . Both CCR5 and CXCL10 are important chemokines and can regulate immune responses through the activation and recruitment of immune cells, such as T-lymphocytes, macrophages, and immature dendritic cells [22, 23] . Previous studies have shown that both CCR5 and CXCL10 are involved in the development of arthritis [24, 25] . During the development of gouty arthritis, chemokines and its receptor, such as CCR5 and CXCL10, may play important roles in the inflammatory reactions or tissue damages. Considering the important roles of CCR5/CXCL10 in the development of gouty arthriti, drugs targeting CCR5/CXCL10 may new therapeutics for acute gouty arthritis [26] . In our study, the combination of sodium alginate and resveratrol significantly reduced the levels of CCR5 and CXCL10 in both the serum and the synovial fluid when compared with colchicines or resveratrol alone (Fig. 2, Fig. 3 ). The outcomes above further prove the superior effect of sodium alginate in combination with resveratrol over colchicines alone or resveratrol alone. However, the findings in our study need the validation from clinical trials. Currently, there is no clinical trials aimed to assess the treatment effect of the combination of sodium alginate and resveratrol on acute gouty arthritis, and further clinical trials are needed to assess the promising effect.
In summary, the combination of sodium alginate and resveratrol has better effect over colchicines in treating MSU-induced acute gouty arthritis. However, more studies are needed to further explore the mechanism underline the effects of resveratrol and sodium alginate on gouty arthritis. In addition, further clinical trials are needed to validate the finding in present study.
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